Chào mừng trở lại
Bấm vào "Đăng nhập " để đồng ý Điều khoản dịch vụ Cointime và xác nhận rằng Chính sách bảo mật Cointime là dành cho bạn.
Tham gia Cointime
Đã có tài khoản?
Bấm vào "Đăng nhập " để đồng ý Điều khoản dịch vụ Cointime và xác nhận rằng Chính sách bảo mật Cointime là dành cho bạn.
Đăng nhập với email
Đăng nhập với
Email của bạn
Đăng ký
Bấm vào liên kết chúng tôi gửi tới để đăng nhập
Nhấp vào liên kết chúng tôi đã gửi tới để đăng ký.
EnGeneIC
company
About
EnGeneIC develops and commercializes the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells.
- 11 - 50
Highlights
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $10M
- Industries
- Biotechnology,Life Science,Therapeutics
- Founded date
- Jan 1, 2000
- Number Of Employee
- 11 - 50
- Operating Status
- Active
EnGeneIC is a bioscience company, develops and commercializes novel concepts in the targeted delivery of chemotherapeutics for cancer drugs in-vivo. The company’s drug/siRNA delivery vehicles offer a range of choices for optimizing the delivery of clinically meaningful drug and siRNA doses to target cancer cells in-vivo. It serves customers in Australia, Singapore, Japan, and India. The company was incorporated in 2000 and is based in Lane Cove West, Australia.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$10M
EnGeneIC has raised a total of
$10M
in funding over 2 rounds. Their latest funding was raised on
Jan 6, 2015 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jan 6, 2015 | Series B | $10M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
EnGeneIC is funded by 1 investors.
Foley Ventures
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Foley Ventures
|
— | Series B |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
